Clinical trial of regenerative medicine for hemophilic arthropathy using human mesenchymal stem cells

Clinical trial of regenerative medicine for hemophilic arthropathy using human mesenchymal stem cells - Regenerative medicine for hemophilic arthropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009428

Enrollment

Registered

2013-04-01

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilic knee arthropathy

Interventions

Joint infusion of human mesenchymal stem cells

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: progressive hemophilic knee arthropathy non-inhibitor covered with prophylaxis treatment

Exclusion criteria

Exclusion criteria: DM Antibody(+) of HCV, HIV liver dysfunction anemia renal dysfunction drug allergy

Design outcomes

Primary

Measure	Time frame
Safety of the transplanted patients	—

Secondary

Measure	Time frame
1)repair of cartilage evaluated by MRI 2)Improvement of clinical symptoms and joint function	—

Countries

Japan

Contacts

Public Contacthideyuki takedani

IMUST hosipital Research Hospital of the Institute of Medical Science The University of Tokyo

takedani@ims.u-tokyo.ac.jp0334438111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026